Hepatitis C: Can It Be Cured? What Drugs Work Best

Research-informed explainer — last updated April 12, 2026

Yes — hepatitis C can be completely cured. Modern oral antiviral drugs called direct-acting antivirals (DAAs) eliminate the virus in more than 95% of patients, typically within 8 to 12 weeks of treatment. A cure means the virus is undetectable in the blood 12 weeks after finishing the medication and stays that way — a milestone called sustained virologic response, or SVR.

This answer represents a dramatic shift from where medicine stood just 15 years ago. Treatments available in the early 2010s required weekly injections, caused significant side effects, and cured only about half of patients. The research grounding this article includes work from infectious disease specialists at Johns Hopkins who helped define how hepatitis C behaves, how to monitor for liver damage, and how treatment response differs across patients.

What "cured" actually means

Sustained virologic response (SVR) is the medical term for cure. It means no hepatitis C virus (HCV) RNA is detectable in the blood 12 weeks after finishing treatment. Once someone achieves SVR, the virus essentially never comes back — the relapse rate after SVR is below 1% in most studies.

What SVR does not reverse automatically is liver damage that has already occurred. If significant scarring (fibrosis or cirrhosis) developed before treatment, that damage can improve over time once the virus is gone, but it may not fully resolve. This is one reason infectious disease specialists encourage getting tested and treated before cirrhosis develops.

How direct-acting antivirals work

DAAs target specific proteins the hepatitis C virus needs to copy itself. Different drug classes hit different steps in the viral replication cycle. Most current regimens combine two or three agents in a single daily pill and treat multiple HCV genotypes — the slightly different viral strains that vary by region.

The landmark SPRINT-2 trial published in the New England Journal of Medicine showed how much the earlier generation of protease inhibitors improved on interferon alone: adding boceprevir to peginterferon and ribavirin significantly increased SVR rates for untreated patients with genotype 1 HCV [2]. That generation of drugs has since been replaced by all-oral, interferon-free regimens that are more effective and far better tolerated.

A 2017 systematic review in Annals of Internal Medicine examined the evidence base for oral DAA regimens across diverse patient populations, including people with cirrhosis, HIV coinfection, and chronic kidney disease. The review confirmed that SVR rates above 95% are achievable even in these harder-to-treat groups, though drug selection and duration can vary [1].

Which drugs are used today

Current first-line regimens approved by the FDA include:

• Sofosbuvir/velpatasvir (Epclusa) — one pill daily for 12 weeks, treats all 6 HCV genotypes
• Glecaprevir/pibrentasvir (Mavyret) — one pill daily for 8 weeks for most treatment-naive patients without cirrhosis
• Sofosbuvir/velpatasvir/voxilaprevir (Vosevi) — reserved for patients who have tried and failed other DAA regimens

Treatment duration and drug choice depend on genotype, prior treatment history, and whether cirrhosis is present. An infectious disease specialist or hepatologist will select the right regimen based on your specific situation.

Why some patients are harder to treat

Before DAAs became available, researchers discovered that a genetic variation near the IL28B gene — which codes for a type of interferon — was one of the strongest predictors of whether someone would respond to interferon-based therapy. Patients with certain IL28B variants had dramatically better odds of clearing the virus [3]. This pharmacogenomic insight was important at the time, and the research shaped how trials were designed.

With modern DAAs, IL28B genotype matters much less because the drugs work through a completely different mechanism. That said, a few patient groups still see somewhat lower SVR rates and may need longer treatment or additional drugs: those with advanced cirrhosis (especially decompensated cirrhosis), those with certain rare genotypes, and those who have previously failed NS5A inhibitor-containing regimens.

Monitoring liver health before and after treatment

Even before treatment starts, knowing how much liver damage has already occurred affects clinical decisions. A score called FIB-4 — calculated from a patient's age, platelet count, and two liver enzymes (AST and ALT) — is a widely used noninvasive way to assess fibrosis. Research published in Hepatology validated that a FIB-4 score below 1.45 identifies patients at low risk for advanced fibrosis with 90% sensitivity, allowing many patients to avoid liver biopsy [4].

After achieving SVR, patients with pre-existing fibrosis still need periodic liver ultrasound surveillance for liver cancer (hepatocellular carcinoma), because the risk, while reduced, does not disappear entirely once cirrhosis has already developed.

Hepatitis C and HIV coinfection

People with both HIV and hepatitis C face additional complexity. Early research from Johns Hopkins found that coinfection with HCV raises the risk of liver-related complications from antiretroviral therapy, particularly with certain older HIV drugs [5]. Later work from the same institution showed that HIV-positive patients on effective antiretroviral treatment can have near-normal life expectancy [6] — but this benefit is substantially reduced if underlying hepatitis C is left untreated and progresses to cirrhosis.

Current guidelines recommend treating HCV in all HIV-coinfected patients regardless of liver fibrosis stage. DAAs achieve SVR rates comparable to those in HIV-negative patients, though drug-drug interactions between HCV regimens and some antiretrovirals require careful review before prescribing.

Questions to ask your doctor

• Which HCV genotype do I have, and does that change the drug choice or treatment duration?
• Do I need a FIB-4 score or any imaging before starting treatment to assess my liver?
• Are there drug interactions between HCV treatment and any medications I currently take?
• After I achieve SVR, will I still need regular liver monitoring, and for how long?
• Is there any risk of reinfection after being cured, particularly if I was exposed through injection drug use?
• Does my insurance cover the preferred regimen, and what assistance programs are available if not?

The bottom line

Hepatitis C is one of the few chronic viral infections that can now be completely eliminated with medication. Oral DAA regimens cure more than 95% of patients in 8 to 12 weeks, with minimal side effects compared to older treatments. The virus is gone after SVR — but liver damage that accumulated before treatment may persist, which is why getting tested and treated early matters. If you have ever been exposed to HCV or fall into a risk group, talk to an infectious disease specialist about testing and, if positive, about which treatment is right for your situation.